Lv2
188 积分 2024-08-20 加入
Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy
1天前
待确认
Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy
1天前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2个月前
已完结
Multivariate meta‐analysis
3个月前
已完结
Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia
3个月前
已完结
Benefit with MRD-guided treatment in CLL
3个月前
已完结
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
4个月前
已完结
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
4个月前
已完结
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
4个月前
已完结
Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia
4个月前
已完结
皖公网安备34019202002308
